Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injections such as Mounjaro (tirzepatide) and Wegovy (semaglutide) are not licensed to treat fatigue or boost energy directly, yet many people on these medicines do report feeling more energetic over time. The honest answer is: it depends on where you are in treatment. In the first few weeks, tiredness is common. As weight reduces and metabolic health improves, many people find their energy levels lift noticeably. These are prescription-only weight loss injections requiring clinical assessment; whether they are suitable for you is a decision made with a prescriber, not a product you can self-select.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Starting a GLP-1 medicine or its dual-agonist equivalent is a real physiological shift. Gastric emptying slows, appetite drops, and your body is taking in fewer calories than it was used to. That adjustment frequently shows up as fatigue. The NHS patient information for tirzepatide lists tiredness among the common early side effects, alongside nausea and digestive changes.
It helps to understand the sequencing. The starter dose (2.5 mg for tirzepatide, 0.25 mg for semaglutide) exists primarily so your system acclimatises gradually; it is not the dose that drives significant weight change. That means the tiredness some people feel early on arrives before most of the weight-loss benefit does. Knowing this makes the first few weeks easier to sit with.
The practical checking habit worth building: before bed each night in the first fortnight, glance at how much water you have drunk. Mild dehydration from reduced appetite or a bout of nausea amplifies tiredness considerably, and it takes under a minute to notice whether your intake has slipped. Most adults on these medicines benefit from consciously keeping fluids up, especially on days when food feels unappealing.
For most people, the early fatigue lifts within two to four weeks. As the body adjusts to its new intake and the gastrointestinal side effects settle, reported energy levels tend to stabilise and then, gradually, improve. This is not a placebo effect. Carrying less body weight reduces the mechanical load on joints, lowers resting heart rate in many people, and (if excess weight was disrupting sleep) often improves sleep quality meaningfully.
Sleep apnoea, for example, is more common among people with obesity, and the NHS England guidance on weight management injections lists obstructive sleep apnoea as one of the weight-related conditions that can qualify someone for treatment. As weight reduces, sleep apnoea frequently improves, and better sleep is one of the most direct routes to feeling more awake during the day.
Blood pressure and cholesterol often improve alongside weight loss too. None of these changes happen overnight, but by months two or three, the picture is usually clearer. If you are weighing up which medicine to start with, our page on the novo weight loss injection explains how semaglutide works and what to expect from it. You can read more about the broader process on the weight loss treatment overview.
Once settled on a maintenance dose, most people do not think of fatigue as a dominant feature of their experience. That said, tiredness at this stage warrants attention rather than assumption. Possible causes range from the harmless (a disrupted night, a busy week) to the medically relevant.
A few signs that should prompt a conversation with a prescriber rather than waiting: fatigue accompanied by severe or persistent stomach pain (pancreatitis is an infrequent but serious side effect of GLP-1 medicines, the MHRA highlighted this in its January 2026 Drug Safety Update), dizziness, a significant drop in urine output, or low mood. None of these are common, but they are the signals that distinguish ordinary tiredness from something worth investigating.
It is also worth checking whether calorie intake has fallen too sharply. Medicines like Mounjaro are very effective appetite suppressants, and some people under-eat to the point where protein and micronutrient intake suffers. A prescriber or dietitian can help calibrate this; our frequently asked questions cover some of the nutrition questions that come up most often.
If you are in the process of exploring whether a GP can give weight loss injections and what that pathway involves, or you want to understand the full range of treatment options and how assessment works, both pages lay out the process clearly. For those already injecting and wondering about technique, the guide to self-injection covers practical steps that reduce discomfort and site reactions, which in turn support consistency.
On the question of cost, our weight loss injections price page explains what a legitimate private prescription includes and why clinical oversight is part of the price, not an optional extra. If you are also thinking about donating blood while on treatment, our page on whether you can give blood on weight loss injections sets out the current guidance and what to discuss with your donation centre.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.